H2020-NMBP-TR-IND-2020-twostage
Next generation organ-on-chip (RIA-LS)

Tumor-LN-oC

Tumor and Lymph Node on Chip for cancer studies

Starting date of the project: 01/05/2021
Duration: 48 months

= Deliverable D16.2 =

Dissemination plan

Due date of deliverable: 31/10/2021
Actual submission date: 29/10/2021

Responsible WP: Kristin Aldag, AMI
Responsible TL: Kristin Aldag, AMI
Revision: V1.0

Dissemination level		
PU	Public	X
PP	Restricted to other programme participants (including the Commission Services)	
RE	Restricted to a group specified by the consortium (including the Commission Services)	
CO	Confidential, only for members of the consortium (including the Commission Services)	

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 953234.

AUTHOR

Author	Institution	Contact)
Kristin Aldag	AMI	aldag@amires.eu

DOCUMENT HISTORY

Document version	Date	Change
V0.1	01/10/2021	First Draft
V0.2	28/10/2021	Revised by Coordinator
V1.0	29/10/2021	Final version

VALIDATION

Reviewers	Name	Validation date
Work Package Leader	Kristin Aldag	28/10/2021
Project Manager	Kristin Aldag	28/10/2021
Coordinator	Ioanna Zergioti	29/10/2021

DOCUMENT DATA

Keywords	Dissemination, communication
Point of Contact	Name: Kristin Aldag Partner: AMI Address: Stavitelská 1099/6, 16000 Prague Phone: +420 603 334 830 E-mail: aldag@amires.eu
Delivery date	29/10/2021

DISTRIBUTION LIST

Date	Issue	Recipients
29/10/2021	V1.0	EC via portal, partners via OwnCloud, general public via website

DISCLAIMER

Any dissemination of results reflects only the authors' view and the European Commission Horizon 2020 is not responsible for any use that may be made of the information Deliverable D16.2 contains.

Executive Summary

Timely and effective internal and external communication, as well as broad dissemination of results are an essential part of every research and innovation project. This ensures that the gained knowledge or exploitable outcomes can benefit the whole society, and that any duplication of research and development activities is avoided.

In the framework of Tumor-LN-oC Work Package 16 (Communication, Dissemination, and Exploitation planning), we present herein Deliverable 16.2, which has been developed as a working document outlining the plan for the dissemination strategy and tools to be used during the project. This communication and dissemination strategy for the Tumor-LN-oC project has been developed as a preliminary plan to fulfil the aforementioned goals. This plan ensures that all possible dissemination routes are identified and used throughout the course of the project. Additional routes will be investigated continuously. This document will be updated if applicable.

It is vital that the dissemination of the project's achievements should never jeopardise protected intellectual property (e.g. patent, product design) or further industrial application. In order to address this, before any activity (e.g. publication, presentation, etc.), strict rules of prior notice to all partners will be applied according to EC guidelines and the Tumor-LN-oC Consortium Agreement. Partners will have the opportunity to refuse dissemination of their own know-how (background or results) by others when it could potentially harm their interests.

Table of contents

1. Introduction 5
2. Dissemination and communication rules 5
2.1. Internal communication 5
2.2. External communication 6
2.3. Guidelines for partners 8
2.4. Publication policy and open access 9
3. Tumor-LN-oC dissemination and communication strategy 9
3.1. Target audience 9
3.2. Strategy structure 10
3.3. Visual identity 11
3.4. Tumor-LN-oC logo 11
3.5. Tumor-LN-oC website 12
3.6. Tumor-LN-oC dissemination materials 12
3.7. Tumor-LN-oC Templates 15
3.8. Tumor-LN-oC Social media 16
3.9. EAB cooperation 17
4. Publication of Tumor-LN-oC results 17
4.1. Presentation at conferences, symposia, meetings 17
4.2. Scientific publications 19
4.3. Other forms of publications 19
5. Conclusions 20
6. Degree of Progress 20
7. Dissemination level 20

List of figures

Figure 1: Tumor-LN-oC timeline for publication approval 7
Figure 2: Tumor-LN-oC Dissemination Recording Plan – Events 8
Figure 3: Tumor-LN-oC Dissemination Recording Plan – Press and Media 8
Figure 4: Tumor-LN-oC Dissemination Recording Plan – Scientific Publications 8
Figure 5: Tumor-LN-oC Visual Identity 11
Figure 6: Tumor-LN-oC Logo 11
Figure 7: Tumor-LN-oC Homepage 12
Figure 8: Tumor-LN-oC Factsheet 13
Figure 9: First Press Release of Tumor-LN-oC 14
Figure 10: Tumor-LN-oC PowerPoint Template 15
Figure 11: Tumor-LN-oC Deliverable template 15

List of tables

Table 1: Post and articles shared about Tumor-LN-oC as of 25/10/21 16
Table 2: Past and planned participation in conferences and similar events as of 25/10/21 18

1. Introduction

Deliverable D16.2 Dissemination plan is part of the task T16.1 Dissemination plan & high impact collateral. The task states that a Tumor-LN-oC dissemination and communication plan will be prepared. It will comprise the internal (within the Consortium) and the external (outside the Consortium) spheres, the identification and selection of relevant audiences, the identification and selection of adequate communication channels, the definition of the information to communicate at each stage of the Project and the identification of public key organisations as well and professional operators within the EU and at the national level, deemed influential in the sector, so that dissemination efforts are leveraged. Dissemination targets, means and routes will be identified in the plan. Through this Task, the online presence will also be managed.

The dissemination and communication strategy outlines the main elements and strategic choices regarding the dissemination and communication activities of the Tumor-LN-oC project towards the most important stakeholder groups. The document will enable the project team to properly plan and implement all required dissemination activities in order to achieve the identified main objectives: implementation of communication activities targeted towards different stakeholders, production of publicity materials for project outputs awareness and involvement of the community throughout all phases of the project. Active participation in conferences, workshops, exhibitions and courses, as well as fostering relationships with other framework projects and initiatives (clustering activities) are key initiatives for this plan. The dissemination activities and plan will be updated periodically on the “PANCAIM recording dissemination and plan” Excel file. Information regarding dissemination will also be included in the periodic reports.

2. Dissemination and communication rules

2.1. Internal communication

The Tumor-LN-oC consortium recognises that effective internal communication is one of the most important factors determining the success of this project. It is at least as important as the external communication, although in some cases can easily be overlooked. A partnership that focuses more on external communication with the target groups, thereby neglecting communication flows among themselves, should be at all costs avoided. This is especially relevant for a complex international research and innovation project like Tumor-LN-oC with a consortium composed of institutions who are spread across different countries, and who cooperate on an EU-funded project, since their geographical dispersion alone makes their joint work extremely challenging. Therefore, a proper communication flow must be ensured at all times.

Proper communication flow means that the information is concrete, clear and distributed in a timely manner to all interested parties, whilst maintaining a good balance between insufficient information and too much information.

The main objectives of internal communication activities within Tumor-LN-oC are to:

- Share information among partners;
- Inform constantly about project progress;
- Synchronise activities of the partners and resolve interdependencies;
- Identify problems (if any) and find proper solutions;
- Make decisions on project changes (if any).

Communication among the consortium partners will be carried out in the following manner:

- Physical or online meetings with all project partners are organised every 6 months (M6, M12, M18, M24, M30, M36, M42, M48)
- Project Steering Committee (PSC) teleconferences are organised monthly
- General Assembly (GA) meetings are organised annually
- External Advisory Board (EAB) meetings are organised annually
- Within the individual WPs, the partners communicate on a daily basis.

The consortium has found that this frequency is very effective in that it allows an exchange of information often enough to keep everyone updated, but at the same time doesn't cause an overload of information of meetings. Furthermore, any problematic issues will be immediately dealt with using appropriate solutions proposed in cooperation with involved partners.

To efficiently exchange information and documents internally, Tumor-LN-oC uses a cloud-based management and storage platform (OwnCloud) hosted by AMIRES. All partners have easy access to the Tumor-LN-oC OwnCloud and therefore to the latest information, documents, and templates therein stored.

2.2. External communication

In relation to the external communication, it has to be mentioned that the dissemination of the project's achievements should never jeopardize the potential protection of generated intellectual property (e.g. patent, product design) and further industrial application. Therefore, before any dissemination activity (publication, presentation) strict rules of prior notice to all partners will be applied, according to EC guidelines.

Partners will have the opportunity to refuse dissemination of their own know-how (background or results) by others when it could potentially harm the partner's interests. The Dissemination Manager (Kristin Aldag) in cooperation with the Exploitation Manager (Rudolf Fryček, AMIRES) will follow all the below described approval processes and will act as an internal executive approval body for any dissemination action organised by different partners.

All project outcomes will acknowledge the support of the European Commission as requested by Article 29 (Dissemination of Results, Open Access, Visibility of EU Funding) and Article 38 (Promoting the Action, Visibility of EU Funding) of the H2020 MGA. Unless it goes against their legitimate interests, each beneficiary must disseminate its results by disclosing them to the public by appropriate means (other than those resulting from protecting or exploiting the results), including in scientific publications (in any medium). This does not change the obligation to protect results in Article 27, the confidentiality obligations in Article 36, the security obligations in Article 37 or the obligations to protect personal data in Article 39, all of which still apply. The process of dissemination can be found in more detail (e.g. time schedule for prior notice and partner's approval) in the signed Consortium Agreement.

According to article 8.4.2 of the Consortium Agreement ("Dissemination of Results"), during the Project and for a period of 1 year after the end of the Project, the dissemination any material and/or own results by one or several Parties including but not restricted to publications and presentations, shall be governed by the procedure of Article 29.1 of the Grant Agreement subject to the following provisions:

- Prior notice of any planned publication shall be given to the other Parties at least 30 calendar days before the publication. Any reasonable objection to the planned publication shall be made in accordance with the Grant Agreement in writing to the Coordinator and to the Party or Parties proposing the dissemination within 20 calendar days after receipt of the notice. If no objection is made within the time limit stated above, the publication is permitted. (Figure 1).
- Objections are justified if the protection of the objecting Party's Results or Background would be adversely affected or if the proposed publication includes Confidential Information of the objecting Party or if the objecting Party's legitimate interests in relation to the Results or Background would be significantly harmed. The objection has to include a precise and reasonable request for necessary modifications.

- If an objection has been raised, the involved Parties shall discuss how to overcome the justified grounds for the objection on a timely basis (for example, by an amendment to the planned publication and/or by protecting information before publication) provided that the objecting Party shall not unreasonably continue the opposition if appropriate measures are taken following the discussion.



Figure 1: Tumor-LN-oC timeline for publication approval as outlined in article 8.4.2 of the Consortium Agreement

The following information shall always be stated in any publication about results from the Tumor-LN-oC project: "This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 953234, project Tumor-LN-oC."

The procedures to allow all dissemination materials to be quality assured, including both the content and layout, are established with the aim of checking: (i) the messages transmitted outside of the consortium, including the suitability of the messages for the people addressed, emphasising the benefits and relevance for industry (when applicable); (ii) the technical contents in order to ensure the quality of achieved scientific and research objectives; (iii) that scientific papers and publications contain sufficient reference to the project; and (iv) layout quality and overall suitability.

A role of a Dissemination Manager (WP16 Leader, Kristin Aldag, AMI) has been established in order to plan, follow, undertake and monitor the planned communication and dissemination activities. Regular contact with all Work Package Leaders will ensure timely communication and dissemination of project outcomes and results.

2.3. Guidelines for partners

The European Commission is encouraging the Dissemination Leaders to record, track, monitor, coordinate and report all the project dissemination activities (publications, participation in events, contributions within press and media) with dedicated deliverables and updates within the Periodic Reports. An Excel file has been prepared in order to track each partner's contribution, keep a complete list of possible future actions and monitor/assess each dissemination activity. This file, created at the very beginning of the project, is composed of three different sheets: Events (Figure 2), Press & Media (Figure 3) and Scientific publications (Figure 4). The tables include information about each dissemination activity performed within the project (type and title, URL and references, targeted public and participants, date, location, Tumor-LN-oC OwnCloud partner responsible for such dissemination, visibility level, etc.) and associated methods (attendance, abstract submission, poster show, distribution of materials like fact sheet, newsletter, etc., oral presentations, DEMO/video show, stand/booth, press releases, post in social media, interviews and videos, etc.). It is distributed amongst the consortium members and updated internally every 6 months of the Tumor-LN-oC project duration. This updated information will be inserted in the Periodic report towards the EC.

Tumor-LN-oC Dissemination recording plan - Events															
Type of event (*)	Name of event	URL	Date	Place	Partner responsible/ participants	Targeted audience (#)	Number of participants/ Visibility (Ç)	Dissemination activity							
								Atten-dance	Abstract submission	Paper submission	Poster submission	Lecture/ presentation	Brochure/ Newsletter distribution	Video/ DEMO	Booth/ Stand

Figure 2: Tumor-LN-oC Dissemination Recording Plan – Events

Tumor-LN-oC Dissemination recording plan - Press and Media											
Medium	URL	Publication date	Partner responsible / author	Targeted audience (#)	Language	Visibility (Ç)	Publication (press)	Web article	Web post	Visual contents	Interview

Figure 3: Tumor-LN-oC Dissemination Recording Plan – Press and Media

Tumor-LN-oC Dissemination recording plan - Press and Media									
Scientific publication (name of the journal / book)	Publisher	D.O.I. (*)	Title of the Tumor-LN-oC article / abstract / manuscript / thesis	Partner responsible/ main author	Authors	Volume and relevant pages	Date of submission	Date of publication	Language

Figure 4: Tumor-LN-oC Dissemination Recording Plan – Scientific Publications

2.4. Publication policy and open access

Partners agree to generate peer-reviewed articles resulting from projects to an institutional or subject-based repository, for example Europe PMC (https://europepmc.org/) to make their best efforts to ensure open access to these articles, at time of publication or at the latest within six months after publication. Europe PMC is a popular publication repositor for life scientists such as cell biologists and recommended by the EU to use.

The open access will be in line with Article 29.2 H2020 MGA on open access to scientific publication and the "green" (self-archiving) or "gold" (open access publishing) model will be used depending on the strategy of the consortium with regard to the specific peer-reviewed scientific publication.

In line with Article 29.2 H2020 MGA, each beneficiary will ensure open access (free of charge online access for any user) to all peer reviewed scientific publications relating to its results. In particular, they will:

- Deposit a machine-readable electronic copy of the published version or final peer-reviewed manuscript accepted for publication in a repository for scientific publications; moreover, the beneficiary must aim to deposit the research data needed to validate the results presented in the deposited scientific publications.
- Ensure open access to the deposited publication at the latest:
  - upon publication, if an electronic version is available for free via the publisher, or
  - within six months of publication in any other case.
- Ensure open access to the bibliographic metadata that identify the deposited publication.

The Tumor-LN-oC OwnCloud is used as an internal file sharing and collaboration platform which is accessible to all of the consortium partners. The Tumor-LN-oC website will provide information about and links to the scientific publications generated from the Tumor-LN-oC results.

Various research data and results will be collected and generated throughout the duration of the project. The main research results will be shared with the scientific community and general public through the World Wide Web. The emphasis of data management will be on faithful and reproducible record keeping, with an emphasis on transparency and accountability. The consortium has a preliminary plan with respect to managing products of research; data format and content; data access and sharing; re-use and redistribution; and archiving and preservation of access.

3. Tumor-LN-oC dissemination and communication strategy

3.1. Target audience

As an RIA action targeting product-oriented innovation, the communication activities in Tumor-LN-oC are designed so as to ensure that the underlying concept, the findings and the potential impact of the target innovations are conveyed in a clear and comprehensible way to different audiences. The first step of the dissemination activities was to identify and map the different types of target audiences and stakeholders relevant to Tumor-LN-oC's technology. Consequently, the priority was to develop a suitable communication strategy for each one of them.

Target audiences for the dissemination of information about Tumor-LN-oC and its results mainly include:

- **Industry & Potential Investors**
  - Industrial associations, for instance
    - the Microfluidics Association (MFA),
    - Makefluidics,
    - European Society for Biomaterials (ESB),
    - European-Biotechnology Network,
    - European Diagnostic Manufacturers Association,

- **EC Policy Making Bodies, Associations, Committees**
  - Civil Society
    - social fora such as the European Cancer Patient Coalition
  - Key policy-forming bodies, at regional, national and EU level
    - National Ministries of Research,
    - National Ministries of Health,
    - Public authorities
    - relevant EC directorates
    - relevant EU Parliamentary Committees.
  - Health insurance agencies
  - Other relevant organisations
    - e.g. Society for Applied Spectroscopy, American Society of Clinical Oncology (ASCO), the European Society for Molecular Oncology (ESMO), European CanCer Organisation (ECCO), Cancer Core Europe

- **Academia & Scientific Community**
  - The Scientific Community:
    - Research groups, Institutes, Universities and key opinion leaders within the fields of OoC and microfluidics, photonics and spectroscopy, biomedical instrumentation and personalised medicine
  - Scientific Associations:
    - E.g. the European Organ-on-Chip Society (EUROoCs),
    - the European Society of Medical Oncology,
    - European Association for Cancer Research (EACR),
    - Nordic Organ-on-a-Chip Network,
    - European Material Research Society (EMRS),
    - SPIE photonics Europe,
    - Photonics21.

- **General Public**

3.2. Strategy structure

Tumor-LN-oC communication and dissemination activities are suggested as follows:

- development and maintenance of the project webpage
- preparation of the Tumor-LN-oC dissemination materials
- organization of the Tumor-LN-oC events
- publication of the Tumor-LN-oC results
  - at key conferences in Europe
  - in relevant scientific and industrial journals
- EAB cooperation through member´s associations

3.3. Visual identity

Tumor-LN-oC's visual identity is compromised of the logo, the purple-yellow-black colours, and the font (Calibri 11). A document summarising the project's visual identity was created and is accessible to partners. The website, all dissemination materials and all templates used for internal and external communication are based on these guidelines.



Figure 5: Tumor-LN-oC Visual Identity

3.4. Tumor-LN-oC logo

The project logo was prepared by the WP6 leader (AMI) and it is used in all the project related advertising materials including templates, the website, leaflets, posters and brochures. The "M" is shown in the shape or a lung to allude to the project's focus on lung cancer, as well as its connection with machine leading and artificial intelligence. The "O" shows a simplified icon of the Organ-on-Chip technology that is to be developed during the project.

Figure 6: Tumor-LN-oC Logo

3.5. Tumor-LN-oC website

The Tumor-LN-oC project website (https://tumor-ln-oc.eu/) has been set up in order to increase public awareness about project aims and to get to potential end users. The Tumor-LN-oC website has been operational since August 2021, and functions on both desktop and mobile devices. It allows visitors to get to know the partners behind the project and will be regularly updated with any project-related news and events. All public deliverables and dissemination materials (flyers, posters, press releases) will be made available for download here.



Figure 7: Tumor-LN-oC Homepage

The website has been created in Open Source software called WordPress. WordPress started as a blogging system but has evolved to be used as full content management system, that is completely customisable and can be used for almost anything within the field of web design. It allows fast and reliable customisation and has a user-friendly back-office environment which is a key for allowing easy updates to the website, especially the "News and Events" section, and allows file uploads.

The website is available for public access and will be actively maintained during the project. The site will remain active for a period of three years after the end of the project. The functionality and structure of the Tumor-LN-oC project website are described in more detail in DEL16.1: Project website launch. The website provides acknowledgement of EU funding as follows: "This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 953234, project Tumor-LN-oC."

The project will also be promoted through the websites of Tumor-LN-oC partner organisations (e.g. News sections, projects sections etc.) and in the social media channels of the partners.

3.6. Tumor-LN-oC dissemination materials

Several types of dissemination materials will be prepared during the course of the project in order to inform wide and various audiences on the Tumor-LN-oC project and its development. These include:

- Project fact sheet/onepager
- Project leaflets
- Posters (presented on events and at the partner's facilities in areas with guest traffic)
- Project Rollups

3.6.1. Tumor-LN-oC factsheet/One-Pager

A project fact sheet was prepared in the form of a one-pager to provide general project information, a description of the Tumor-LN-oC ambition and expected impact as well as information on partners and project contacts. Partners have access to the digital version of the factsheet via the OwnCloud and are able to print and distribute it as desired.



H2020 project:

Tumor and Lymph Node on Chip for cancer studies

Tumor-LN-oC

About project

Tumor-LN-oC proposes the development and validation of a TRL 5 tumor-lymph node-on-chip (Tumor-LN-oC) platform composed of 3D tissue models and microfluidic chips which will connect surgically removed human primary tumors and LN tissue from the same lung cancer patient. This will serve as a "biological twin" of the patient and will allow us to study the interaction of primary tumors with LNs for individual patients.

Using sensitive proteomic and molecular approaches it will characterize the soluble signals that neutralize the immune response and allow tumor cells to metastasize to the LNs and to use them as spring boards for further dissemination. This will enable the use of existing drugs, or the development of new ones that could reverse this process and inhibit tumor growth and dissemination. It will also allow the identification of novel biomarkers characterizing metastatic cells which could also be exploited therapeutically. Moreover, by employing novel imaging approaches, Tumor-LN-oC will generate a spectral "fingerprint" of migrating/metastasizing cells which could be used for diagnostic purposes in tumor and lymph node biopsies.

The proposed technologies will provide added value to the EU cancer diagnostics and pharmaceutical industries and lower the barriers associated with the application of OoC technology in disease diagnosis and therapy.

Expected impact

- Verifiable progress in the application of Organ-on-Chip technologies for in-vitro research
- Reduction of the need for animal and clinical testing
- Lowering of barriers for application of Organ-on-Chip technology
- Improved competitiveness and attractiveness of the European biomedical and healthcare sector
- Increased awareness and knowledge about medical regulatory policies and requirements, especially by academics and SMEs

TUMOR LN-oC

Project Facts:

Start date: 01/05/2021
End date: 30/04/2025

Duration in months: 48

Project budget: €5,77 M

Research and Innovation action Lump Sum

Grant Agreement: 953234

Call: H2020-NMBP-TR-IND-2020-twostage

Topic: DT-NMBP-23- 2020 Next generation organ-on-chip (RIA-LS)

Keywords:
Organ on Chip, Lymph Node, Tumor on chip, tumor migration, bioprinting, microfluidics

Consortium:

ICCS	GR
TU/e	NL
BRFAA	GR
AAU	FI
ALPES	CH
RAY	UK
TUW	AT
ELV	FR
PhosPrint	GR
ASPH	ES
AMI	CZ

Project coordinator:

Prof. Ioanna Zergioti
Institute of Communication and Computer Systems (Greece)
zergioti@central.ntua.gr

Project manager:

Kristin Aldag
AMIRES s.r.o. (Czech Republic)
aldag@amires.eu

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 953234.

Figure 8: Tumor-LN-oC Factsheet

3.6.2. Project leaflets

Project leaflets and further promotional, written and audio-visual digital materials (brochures, leaflets, newsletters) will be prepared in WP17 to provide at glance the project overview, goals, impact, partners and, if applicable, first results, to those interested in the topic.

All promotional materials will be regularly reviewed and updated when needed. Partners will have access to the digital version of any leaflets or brochures created via the OwnCloud and will be able to print and distribute the materials as desired.

3.6.3. Tumor-LN-oC roll-up

A project roll-up will be prepared which will include general project information, a description of the Tumor-LN-oC concept and approach including project logo, logos of partners and the webpage link. More roll-ups will be prepared for partners to use at events they will attend. Further posters displaying scientific content could be developed by partners and presented during scientific symposia and conferences, demonstrating tangible results along with project achievements.

3.6.4. Tumor-LN-oC poster

A high-quality project poster will be created, which will be a graphical synopsis of the overall concept and will be displayed in every available booth or stand and other public places. The poster will be updated on a yearly basis and will be made available to partners via the OwnCloud to print and distribute at their discretion.

3.6.5. Tumor-LN-oC video spot

A short video spot about the project will be made and distributed through the project's communication channels. Video as being a different tool might attract another audience and at the same time support the already established communication and dissemination routes. It will also help to make the highly specialized technological objectives of the project more accessible and understandable to the public, and give a face to the consortium.

3.6.6. Press releases

The aim of the press releases is to attract favourable media attention and provide publicity for the project and its events. Press releases to European media, OoC and patient associations and hospital press and to the communication offices of the participants' institutions and to the EC communication services will be drafted when appropriate.

The first Tumor-LN-oC press release was published on 7th of September 2021 in M5 of the project (Figure 9). It contains more information on the topic of the project, as well as its objectives and expected impact and introduces the consortium partners. The document is publicly available on the website and accessible here.

Further press releases will be produced during the course of the project and will be connected with important results / milestones achieved. All the press releases published by the project are available on the project website, in the section PROJECT -> RESULTS.

Press releases will also been published by individual partners to present their involvement in the project.

Press release

Tumor-LN-oC: Tumor and Lymph Node on Chip for cancer studies

Athens, September 2nd, 2021: Lung cancer is the leading cause of death (1.8 million worldwide, 267K in Europe) and accounts for 1/5 of total cancer deaths. It is believed that up to 70% of metastases occurs through the lymphatic system with lymphatic vessels and lymph nodes (LN) mediating the process, while the rest of them are of hematogenous origin and occur through the blood stream. LN metastasis is an independent indicator of poor prognosis. LNs are responsible for the immune response against external threats as well as the elimination of tumor cells which are considered foreign entities. Tumor cells however, have found ways to escape the immune system and even colonize LNs, which would be considered an otherwise "hostile" environment. Initially, this is achieved through secreted signals that travel to the lymph node and prepare the field, while later cancer cells migrating and homing the LN actively suppress the local immune response. Nowadays, immune response reactivation is the basis of immunotherapy success in cancer treatment. Understanding how tumors shape the LN environment and how tumor cells metastasizing to the LNs are able to suppress the immune response locally is a breakthrough, and it will help us identify novel biomarkers, and possibly targeted therapies which could be combined with existing anticancer therapies. Studying the metastatic process in real time, and doing so for individual cancer patients in a personalized manner that would also enable parallel preclinical drug testing of multiple drugs and combinations, is not possible with current methodologies.

Figure 9: First Press Release of Tumor-LN-oC, 02.09.2021

3.7. Tumor-LN-oC Templates

Templates in the Tumor-LN-oC design are available to partners on the OwnCloud platform. Templates have been created for:

- PowerPoint Presentations (Figure 10)
- Project Deliverables (Figure 11)



Figure 10: Tumor-LN-oC PowerPoint Template



Figure 11: Tumor-LN-oC Deliverable template

Partners are encouraged to use the available templates for any internal and external documents that will be created during the course of the project.

Further templates will be created by the project's dissemination manager when it is considered beneficial, e.g. for social media posts.

3.8. Tumor-LN-oC Social media

Tumor-LN-oC will also be represented through social media pages (i.e. LinkedIn, Twitter) to allow for easier communication with to larger audiences, the general public and industrial end users. At the same time, the consortium considers these bi-directional communication platforms an excellent means to receive feedback from the users' community, citizens and Tumor-LN-oC -related organization.

Short news stories about the Tumor-LN-oC project and its development will be prepared and shared on the identified tools, especially during events, conferences, and symposiums.

Social Media channels of partners such as LinkedIn, YouTube, Twitter, etc. will be also utilized by the respective marketing and communication departments to share news and information about Tumor-LN-oC. As of 25/10/2021, following articles and posts about Tumor-LN-oC have been shared (non-exhaustive list):

Table 1: Post and articles shared about Tumor-LN-oC as of 25/10/21

Partner	Medium	Date	Link
AAU	Åbo Akademi University News	10/09/2020	https://www.abo.fi/nyheter/finansiering-for-ny-plattform-som-ska-gora-cancerbehandling-mera-exakt/
ASPH	Website	10/09/2020	https://www.asphalion.com/news/tumor-ln-oc-tumor-and-lymph-node-on-chip-for-cancer-studies/
ICCS	Website	04/05/2021	https://www.iccs.gr/blog/2021/05/04/tumor-ln-oc/
PhosPrint	Website	07/05/2021	https://www.phosprint.eu/
AMI	Twitter	07/05/2021	https://twitter.com/AMIRES_EU/status/1390631247370760194
AMI	Website	08/05/2021	https://amires.eu/tumor-and-lymph-node-on-chip-breakthrough-tumor-ln-oc/
PhosPrint	LinkedIn	13/05/2021	https://www.linkedin.com/feed/update/urn:li:activity:6798518265233584128
ELV	Website	15/06/2021	https://www.elveflow.com/microfluidics-research-horizon-europe/european-projects/tumor-on-chip-technology-tumor-and-lymph-node-on-chip-for-cancer-studies-tumor-ln-oc/
ELV	LinkedIn	17/06/2021	https://www.linkedin.com/posts/elveflow_tumor-on-chip-technology-for-cancer-studies-activity-6811261169475579904-v-Iq/
AMI	Website	01/09/2021	https://amires.eu/tumor-ln-oc-website-has-been-launched/
All	Press release	02/09/2021	https://tumor-ln-oc.eu/wp-content/uploads/2021/09/Tumor-LN-oC-press-release.pdf
PhosPrint	LinkedIn	02/09/2021	https://www.linkedin.com/feed/update/urn:li:activity:6839257512135421953
AMI	Twitter	02/09/2021	https://twitter.com/AMIRES_EU/status/1433415508817240072
ALPES	Website	03/09/2021	https://www.alpeslasers.ch/index.php?a=&entry=330#entry_330
AMI	Website	05/09/2021	https://amires.eu/boosting-organ-on-chip-technologies-for-lung-cancer-research-tumor-ln-oc-issues-first-press-release/
AMI	Twitter	06/09/2021	https://twitter.com/AMIRES_EU/status/1434851815372296197
ALPES	Website	10/09/2021	https://www.alpeslasers.ch/?a=36,154,218
ASPH	Website	10/09/2021	https://www.asphalion.com/news/tumor-ln-oc-tumor-and-lymph-node-on-chip-for-cancer-studies/
ELV	LinkedIn	15/09/2021	https://www.linkedin.com/posts/elveflow_home-tumor-ln-oc-activity-6846775163791400960-Jwbg/
AAU	Website	n d	https://research.abo.fi/en/projects/tumor-lymph-node-on-a-chip

The active sharing of posts on social media and project partners' websites will continue and become more frequent as the project progresses and more results become available.

3.9. EAB cooperation

The Tumor-LN-oC External Advisory Board was created first and foremost in order to support the consortium during the technical specification phase at the start of the project, validation of results and flawless results exploitation. However, the EAB also serves the purpose of increasing the Pan-European concept of this project and provide desirable feedback from other closely related European or national initiatives in the topic of Tumor-LN-oC. The communication with EAB members is ensured through regular meetings (in person or through teleconferences).

The current list of EAB members includes the following representatives:

- **Janny van den Eijnden-van Raaij,** Executive Board Member/Managing Director at hDMT, Institute for human Organ and Disease Model Technologies & Executive Board Member European Organ-on-Chip Society (EUROoCS)
- **J.W.M. (John) Martens**, Professor at the Department of Internal Oncology Erasmus University Medical Center Rotterdam
- **Marleen Krok** – Medical Oncologist at NKI (Netherlands Cancer Institute)
- **Sirpa Jalkanen** – Professor of Immunology at the Institute of Biomedicine of the University of Turku

4. Publication of Tumor-LN-oC results

Publication of Tumor-LN-oC results to relevant scientific and industrial periodicals, journals and key conferences in Europe will be assured throughout the whole project lifetime.

4.1. Presentation at conferences, symposia, meetings

A set of conferences will be selected and articles, papers and posters will be prepared for them. During these events the representatives of the project will have the possibility to communicate the project's scope and possible interaction and exchange with initiatives and projects in related fields.

Tumor-LN-oC findings will be presented in invited talks and seminars in highly prestigious conferences. Some examples of conferences, where presentation on project Tumor-LN-oC will be considered are (the list is not exhaustive):

- MicroTas
- SelectBio
- SciX
- EMRS meetings
- International Conference on Advanced Vibrational Spectroscopy (ICAVS)
- SPIE photonics
- International Conference on Biosensing Technology
- EOS conference in opto-fluidics, World Congress on Biosensors
- Gordon Research Conferences
- EMBO and EMBL conferences and workshops

Once first results of Tumor-LN-oC are available, they will also be presented to relevant industries and potential investors at selected targeted medical equipment tradeshows and fairs. For instance, commercial partners Alpes, Rayfos and PhosPrint plan to participate with presentations and booths in world-renowned events including, but not limited the following:

- EUROoCS annual conferences,
- BioChip Berlin,
- SELECTBIO Organ-on-a-Chip

- SPIE Photonics West,
- SPIE Photonics Europe,
- European Materials Research Society (E-MRS)
- CLEO Conference,
- International Conference on Biomedical Imaging,
- Signal Processing (ICBSP)
- International Conference on Biomedical Engineering and Bioinformatics (ICBEB)
- IPhEB Russia,
- Rommedica,
- Medicine and Health,
- Swiss Medtech Expo,
- Compamed

Additionally, Tumor-LN-oC partner ELV participates annually in major exhibitions and conferences for relevant fields, mainly IVD and Life Sciences. These include for instance:

- Miniaturized Systems for Chemistry and Life Sciences MicroTAS, a yearly conference on microfluidics
- SelectBio, a yearly conference on microfluidics and OoC.

The consortium will employ all available means to ensure at least one invited or keynote talk and two oral presentations per year. Components of the prototype system will be exhibited / demonstrated starting between M24-48, with conceptual designs ready by M6-9. At the moment of M6, participation of, Tumor-LN-oC partners was previously organised or is planned in following conferences and events:

Table 2: Past and planned participation in conferences and similar events as of 25/10/21

Partner	Conference Name	Place and Date	Comment
ICCS	I3D21- Nanotexnology https://www.nanotexnology.com/index.php/i3d	Thessaloniki 06-07.07.2021	Attendance, lecture/ presentation
ELV	MicroTAS2021 https://microtas2021.org/	Palm Springs, CA, USA 10.-14.10.2021	Attendance, Booth, Tumor-LN-oC Dissemination Materials
ELV	Selectbio https://selectbiosciences.com/conferences.aspx	Coronado Island, CA, USA 13.-15.12.2021	Attendance, Booth, Tumor-LN-oC Dissemination Materials
TUW	Spring SciX https://www.springscix.org/	Liverpool 11.-14.04.2022	Attendance, abstract submission, lecture/ presentation
TUW	SPIE Photonics West https://spie.org/conferences-and-exhibitions/photonics-west?SSO=1	San Francisco/ remote 22.-27.01.2022	Attendance, abstract submission, lecture/ presentation
AAU	EMBO Workshop, Building Networks: Engineering in Vascular Biology https://www.embl.org/about/info/course-and-conference-office/events/evb22-01/	Barcelona, Spain 9-11.5.2022	Attendance, lecture/ presentation
PhosPrint	SPIE Photonics Europe https://spie.org/conferences-and-exhibitions/photonics-europe?SSO=1	Strasbourg, France 3.-7.04.2022	Attendance, abstract submission, lecture/ presentation
ELV	MicroTAS2022	Hangzhou, China 23.-27.10.2022	Attendance, Booth, Tumor-LN-oC Dissemination Materials
AAU	Gordon Research Conferences	TBA	TBD
AAU	European Organ-on-Chip meetings	TBA	TBD

4.2. Scientific publications

Tumor-LN-oC scientists and technology leaders have an excellent track record in high impact factor journals and intend to carefully screen and highlight the projects nonpatentable outcomes to increase their publications. Joint publications from different partners are encouraged during the course of the project. Examples of peer-reviewed journals, where contributions from Tumor-LN-oC partners might be expected (the list is not exhaustive):

- Lab on a Chip (RSC),
- Organs-on-a-Chip (Elsevier),
- ACS Photonics,
- Nature Biology,
- Disease Models & Mechanisms (TCB),
- Microfluidics and Nanofluidics (Springer),
- Scientific Reports (NPG).

All publications will be under the open access publishing frame. All publications will have to be first submitted to the Coordinator and to the Innovation Manager in line with the procedure outlined in point 2.2, in order to ensure that IP is not compromised. At least 3 open-access publications per year will be pursued.

4.3. Other forms of publications

Tumor-LN-oC will comply with knowledge sharing arrangement and will actively contribute to CORDIS - periodically, each time after the latest achievements, at least at the beginning and at the end of the project.

5. Conclusions

This document represents the Deliverable D16.2 “Dissemination plan” of the Horizon2020-funded project Tumor-LN-oC. It summarizes the strategy for disseminating the results of Tumor-LN-oC project and the activities planned to give high visibility to the project, its achievements and partners. The dissemination of the project’s achievements should never jeopardize the potential protection of generated intellectual property and further industrial application. Therefore, before any dissemination activity (publication, presentation) strict rules of prior notice to all partners will be applied, and objections possible. The Dissemination Manager in cooperation with the Coordinator will follow the approval processes and will act as an internal executive approval body for any dissemination action organized by different partners.

An Excel file was prepared in order to record each partner’s contribution to the common dissemination effort and publication of the project contents, and dissemination guidelines referencing to the EC Open Access policy are provided to partners. List of main journals have been identified by partners. It is the role of the main author to propose fair and equal distribution of co-authorships and determine the order. Additionally, partners are encouraged to present the Tumor-LN-oC project at national or international events or conferences, which may be interesting for showing results from the Tumor-LN-oC project.

The target audience is defined in the document as well as the corresponding dissemination routes:

- project website, brochures, multimedia and social media are addressed to broad public;
- scientific publications, publications in technology news server and participation to conferences are addressed to the scientific community;
- workshops, events, press releases and newsletters are addressed to potential technology users, policy makers and media, etc;
- and participation in commercial conferences with booths and dissemination materials, as well as demonstrations are addressed to industry and potential investors.

Tumor-LN-oC promotional materials will be created to raise awareness and inform the general public and various identified target audiences about the Tumor-LN-oC project and its development. These materials will be extensively used by Tumor-LN-oC partners whenever they present at conferences, publish in journals and magazines, establish contacts with media, attend exhibitions, organize workshops, etc.

When disseminating the results of the Tumor-LN-oC project, the following sentence will always be included: the acknowledgment of the EU funding: “This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 953234, project Tumor-LN-oC.”

6. Degree of Progress

This deliverable (D16.2) is 100% complete.

7. Dissemination level

The Deliverable D16.2 is public and therefore it will be made available to download on the project’s website.